Medannex unveils positive clinical data on MDX-124 at ESMO 2025
Encouraging anti-tumour activity of first-in-class therapeutic, with no significant toxicity.
Medannex Ltd (Edinburgh) announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.
Preliminary results for the company’s first-in-class antibody targeting annexin-A1 indicate very encouraging anti-tumour activity in patients with advanced solid tumours, and excellent safety and tolerability at doses up to and including 30 mg/kg.
Key findings include:
- Disease control rate of 55% (6/11) in evaluable patients with advanced cancer, across multiple tumour types
- Tumour shrinkage in 75% (3/4) of cholangiocarcinoma patients, including a confirmed partial response
- MDX-124 was well tolerated across all dose levels with no grade 3–4 treatment-related adverse events or dose-limiting toxicities observed to date
Based on these promising early data, Module 2 of the ATTAINMENT clinical trial—evaluating MDX-124 both as monotherapy and in combination with standard-of-care therapies across selected tumour types—will begin enrolment in Q4 2025.
These early data are an encouraging validation of Medannex’s approach to targeting annexin-A1, a key driver of tumour immune evasion. The favourable safety profile and emerging signs of clinical activity give us great confidence as we prepare to expand development into specific tumour indications.
said Chief Investigator Prof. Daniel Palmer, Director of the Liverpool Experimental Cancer Medicine Centre.
Medannex CEO Ian Abercrombie added:
From thirty years working in oncology, I know how rare it is for a therapeutic to shrink tumours without causin g significant toxicity, particularly in Phase 1. We’re very excited about what this could mean for patients as we move to the next stage of clinical development.
